featured
2024 Top Story in Neurology: Neuroprotection in Patients With Parkinson's Disease: Are We There Yet?
Written by
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
- Oosterhof TH, Darweesh SKL, Bloem BR, et al. Considerations on How to Prevent Parkinson's Disease Through Exercise. J Parkinsons Dis. 2024;14(s2):S395-S406.
- Tang H, Lu Y, Okun MS, et al. Glucagon-Like Peptide-1 Receptor Agonists and Risk of Parkinson's Disease in Patients with Type 2 Diabetes: A Population-Based Cohort Study. Mov Disord. 2024 Aug 27. Doi: 10.1002/mds.29992. Online ahead of print.
- Meissner WG, Remy P, Giordana C, et al. Trial of Lixisenatide in Early Parkinson's Disease. N Engl J Med 2024;390(13):1176-1185.
- Pagano G, Taylor KI, Anzures-Cabrera J, et al. Trial of Prasinezumab in Early-Stage Parkinson's Disease. N Engl J Med. 2022;387(5):421-432.
- Pagano G, Monnet A, Reyes A, et al. Exploratory Analysis of PASADENA Open-label Extension Evaluating the Effect of Prasinezumab on the Progression of Motor Signs and Symptoms (S30.006). Neurology. 2024;102(17_supplement_1).
- Pagano G, Monnet A, Reyes A, et al. Sustained Effect of Prasinezumab on Parkinson's Disease Motor Progression in the Open-Label Extension of the PASADENA trial. Nat Med. 2024 Oct 8. Doi: 10.1038/s41591-024-03270-6. Online ahead of print.
- Pagano G, Taylor KI, Anzures Cabrera J, et al. Prasinezumab Slows Motor Progression in Rapidly Progressing Early-Stage Parkinson's Disease. Nat Med. 2024;30(4):1096-1103.
Disclosure statements are available on the authors' profiles: